Document is current

Article History

Received: 21 August 2024

Accepted: 28 March 2025

First Online: 8 April 2025

Declarations

:

: The study was conducted in line with the principles of the Declaration of Helsinki and conducted in accordance with Good Clinical Practice guidelines. The protocol was approved by the ethics committee (Comite Etico de Investigacion Clinica de Navarra, EudraCT: 2017-000232-34, internal code 20/17).

: All patients provided written informed consent before study participation.

: All authors consent to publish the final manuscript.

: Manuel de la Torre-Aláez has received travel grants from Bayer, Eisai, Pfizer, and Roche. Ana Matilla has received consultancy fees from AstraZeneca, Bayer, Eisai/MSD, Roche, and Sirtex Medical; travel grants from AstraZeneca, Bayer, and Boston Scientific. María Varela has received lecture, congress participation, and consultancy fees as well as travel grants from AstraZeneca, Boston Scientific, Eisai/MSD, and Roche. Mercedes Iñarrairaegui has received lecture fees and travel grants from Bristol Myers Squibb. María Reig has received consultancy fees from AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, Eli Lilly, Ipsen, and Roche; lecture fees from Bayer, Bristol Myers Squibb, Eli Lilly, Gilead, Roche, and Universal Diagnostics; travel grants from AstraZeneca, Bayer, Bristol Myers Squibb, and Eli Lilly; research grants (to institution) from Bayer and Ipsen. Jose Luis Lledó has received speaker and consultancy fees from AstraZeneca, Bayer, Eisai, MSD, and Roche. Juan Ignacio Arenas declares no financial interest. Sara Lorente declares no financial interest. Milagros Testillano has received travel grants from AbbVie. Laura Márquez has received speaker fees from Bayer, Eisai, and Gilead; advisory fees from Eisai and MSD. Gemma Iserte declares no financial interest. Josepmaria Argemí declares no financial interest. Carlos Gómez-Martin has received consultancy fees from Amgen, AstraZeneca, Bristol Myers Squibb, Eisai, Hengrui Therapeutics, Merck, and Roche Spain; speaker fees from Eisai and Eli Lilly. Macarena Rodríguez-Fraile has received speaker and consultancy fees from Sirtex Medical. Jose I. Bilbao has received consultancy fees from Boston Scientific, MSD, Sirtex Medical, and Terumo; speaker fees from Sirtex Medical; research grants from Sirtex Medical and Terumo. Richard F. Pollock is director at Covalence Research Ltd, which has received consultancy fees from ALK, AstraZeneca, Dexcom, Eli Lilly, Genmab, Janssen, medac, Medtronic, Menarini, Novo Nordisk, Otsuka/Avanir, Pharmacosmos, Roche Diagnostics, Siemens Healthineers/Varian, Sirtex Medical (including for assistance with the preparation of this manuscript), and Y-mAbs. Johannes Pöhlmann is an employee at Covalence Research Ltd, which has received consultancy fees from ALK, AstraZeneca, Dexcom, Eli Lilly, Genmab, Janssen, medac, Medtronic, Menarini, Novo Nordisk, Otsuka/Avanir, Pharmacosmos, Roche Diagnostics, Siemens Healthineers/Varian, Sirtex Medical (including for assistance with the preparation of this manuscript), and Y-mAbs. Ion Agirrezabal was employed by Sirtex Medical when the present study was initiated and conducted and is now employed by Sanofi. Bruno Sangro has received consultancy fees from Adaptimmune, AstraZeneca, Bayer, Bristol Myers Squibb, Boston Scientific, BTG, Eisai, Eli Lilly, H3 Biomedicine, Ipsen, Merck, Novartis, Roche, Sirtex Medical, and Terumo; speaker fees from AstraZeneca, Bayer, Bristol Myers Squibb, BTG, Eli Lilly, Ipsen, Merck, Novartis, Roche, Sirtex Medical, and Terumo; research grants (to institution) from BMS and Sirtex Medical.